Introduction
Human apo A-IV is a 46-kD apolipoprotein (1) (2) (3) (4) (5) which is synthesized primarily or exclusively in the small intestine in humans (6) (7) (8) . The human apoA-IV gene exists as part of a gene cluster on chromosome 11 with apoA-I and apoC-III and is thought to have arisen by duplication ofthe apoA-I gene (9) . Though its precise function remains unclear, apoA-IV has been proposed to play a role in the metabolism ofboth triglyceride-rich lipoproteins (TRL)' and HDL. In addition to its presence in plasma, apoA-IV has been found in dog peripheral lymph (10) and in human mesenteric and thoracic duct lymph ( 1, 2) and interstitial fluid (1 1, 12) . ApoA-IV has been shown to modulate lipoprotein lipase (LPL) activity (13) , bind to endothelial cells ( 14) , stimulate cholesterol efflux from adipose cells ( 15, 16) , activate lecithin:cholesterol acyltransferase (LCAT) (17, 18) , participate in HDL particle conversion by cholesteryl ester transfer protein (CETP) ( 19, 20) , and bind specifically to hepatic tissue (21, 22) . Weinberg et al. (23) recently demonstrated that apoA-IV exhibits labile reversible binding to HDL3 and proposed that apoA-IV helps to maintain optimal surface pressure for LCAT and CETP activities. As a result of its distribution and in vitro properties, apoA-IV is thought to play a potentially important role in reverse cholesterol transport.
ApoA-IV is a genetically polymorphic apolipoprotein in humans (24) (25) (26) . The major allele, known as apoA-IV-1, has an estimated gene frequency of 0.91, while the most common variant, apoA-IV-2, has a gene frequency of -0.08 (25) (26) (27) (28) (29) (30) . We recently reported that the molecular basis for this common polymorphism is a single G to T substitution in the apoA-IV-2 allele, resulting in the conversion of a glutamine to a histidine at residue 360 of the mature protein (31 ) . This finding has since been confirmed by two other investigators (32, 33) . This single amino acid substitution may have an important effect on plasma lipoprotein metabolism, as heterozygotes for apoA-IV-2 have been reported to have higher HDL cholesterol (28, 30) , lower triglyceride (30, 34) , higher LDL cholesterol (35) , and lower Lp(a) (35) levels than apoA-IV-1/1 homozygotes. Weinberg et al. (36) reported that the apoA-IV-2 isoprotein has more alpha-helical structure, higher affinity for phospholipids, and greater ability to activate LCAT than the apoA-IV-1 isoprotein. These structural and functional differences suggested that apoA-IV-1 and apoA-IV-2 may have different in vivo metabolism.
Kinetic studies of apoA-IV in humans have been limited to the injection of radiolabeled apoA-IV that was reassociated in vitro with ultracentrifugally isolated lipoprotein density fractions before injection into a small number ofindividuals, some 1 of whom were hyperlipidemic (37) (38) (39) . Furthermore, previous kinetic studies have been performed without knowledge of the apoA-IV phenotype ofthe source ofthe purified apoA-IV or of the study subjects. In order to gain further insight into apoA-IV metabolism in humans, we performed a series ofkinetic studies of apoA-IV-1 and apoA-IV-2 in normolipidemic subjects.
Methods
Study subjects. The study subjects were healthy normolipidemic subjects and included 12 apoA-IV-I / 1 homozygotes, 7 apoA-IV-2/ 1 heterozygotes, and 1 apoA-IV-2/2 homozygote. All subjects had normal fasting glucose levels and normal thyroid, liver, and kidney function. 1 wk before the start of the kinetic study, the subjects were placed on an isoweight diet containing 37% of calories as fat (P/S ratio 0.3), 47% carbohydrate, and 16% protein, with 200 mg of cholesterol per 1,000 cal. All subjects gave informed consent, and the study protocol was approved by the Clinical Research Subpanel of the National Heart, Lung, and Blood Institute.
ApoA-IVphenotyping. Phenotyping of apoA-IV was performed on whole plasma as previously described (31, 40) . Briefly, plasma was delipidated according to Menzel et al. (28) and run on an isoelectric focusing (IEF) gel, using a pH range of 5-6 (Pharmalyte; Pharmacia LKB Biotechnology, Uppsala, Sweden). Proteins were electrotransferred to polyvinylidene difluoride membranes (Immobilon-P; Millipore Corp., Bedford, MA). After blocking with 3% bovine serum albumin in PBS, membranes were incubated for 1 h at room temperature with a 1:1,000 dilution of a polyclonal rabbit anti-human apoA-IV antibody raised in our laboratory. Membranes were washed twice with PBS for 10 min, then incubated either with a goat anti-rabbit IgG antibody (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) using 4-chloro-I-naphthol as substrate, or with a gold-labeled goat anti-IgG (Auroprobe; Amersham, Arlington Heights, IL) with silver enhancement, according to the directions of the manufacturers.
Isolation and iodination ofapoA-IV-I, apoA-IV-2, and apoA-I. For isolation of the apoA-IV isoproteins, apoA-IV-l / 1 and apoA-IV-2/2 homozygotes were identified by isoelectric focusing and immunoblotting as described above. Using PCR amplification of genomic DNA followed by DNA sequence analysis as previously described (31, 40) , the apoA-IV-2/2 subject was confirmed to be homozygous for the G to T substitution at codon 360, resulting in the substitution of histidine for glutamine at this residue.
ApoA-IV-I and apoA-IV-2 were isolated from fasting lipoproteindepleted serum as previously described (41 for apoA-IV as described above. Amino acid analysis was consistent with the known amino acid composition of apoA-IV (5, 42).
ApoA-I was isolated from the HDL of a healthy subject with normal lipid values by gel permeation and ion exchange chromatography (43) .
Purified apoA-IV-l, apoA-IV-2, and apoA-I were iodinated by a modification of the iodine monochloride method as previously described (43) . Briefly, lyophilized apolipoproteins were dissolved in a 6 M guanidine-HCl, 1 M glycine buffer, pH 8.5, then 5 mCi of Na 13'I or Na'251I were added, followed by the iodine monochloride. Approximately 0.5 M iodine was incorporated per mole protein. Radiolabeled apolipoproteins were reassociated immediately with separate aliquots of fresh fasting autologous plasma, and samples were extensively dialyzed against sterile PBS. Human serum albumin was added to a final concentration of 10 mg/ml. The iodinated preparations were passed through a 0.22-tim filter (Millipore Corp.) and tested for pyrogenicity and sterility. All samples were pyrogen-free, sterile, and contained no free iodine by radiochromatography. Radiolabeled apoA-IV-l, apoA-IV-2, and apoA-I migrated to the expected positions on both SDS gel electrophoresis and IEF.
Study protocol. 10 subjects received radiolabeled apoA-IV-l and apoA-IV-2 simultaneously, in studies that represented five separate iodinations of these apolipoproteins. Five subjects received radiolabeled apoA-IV-I and apoA-I, and three received radiolabeled apoA-IV-2 and apoA-I. 1 d before injection, the subjects were given an oral potassium iodide solution (900 mg/d in divided doses) that was continued throughout the study. After a 12-h fast, subjects were injected intravenously with autologous plasma containing the radiolabeled apolipoproteins. Blood samples were obtained at 10 min, 1,3,6, 12, 18,24, and 36 h, and on days 2, 3, 4, and 7. Blood samples were drawn into tubes containing EDTA at a final concentration of 0.01 %. Plasma was separated by low speed centrifugation (2,300 rpm for 30 min) at 4°C. Sodium azide and aprotinin were added to each plasma sample at a final concentration of0.05% and 200 KIU/ml, respectively. Urine was collected continuously throughout the study. Radioactivity in plasma and urine was quantitated in a gamma counter (Autogamma 5260; Packard Instrument Co., Downers Grove, IL).
Plasma decay curves were constructed by dividing the plasma radioactivity at each time point by the radioactivity in the 10-min plasma sample. Multiexponential functions were fit to the plasma decay curves utilizing the SAAM30 program (44) . Residence times (RT) were obtained from the areas under the plasma decay curves. The fractional catabolic rates (FCR) are the reciprocals ofthe residence times. Apolipoprotein production rates (PR) were calculated utilizing the formula: PR = (plasma apolipoprotein concentration) X (plasma volume) X (FCR)/(wt [kg]). Plasma volume was assumed to be 4% of total body wt. For apoA-IV-I / 1 homozygotes the FCR's ofapoA-IV-1 were used and for the apoA-IV-2/2 homozygote the FCR ofapoA-IV-2 was used in the determination of the apoA-IV production rates. For the apoA-IV-2/ 1 heterozygotes the means ofthe apoA-IV-l and apoA-IV-2 FCR's were used.
Gelfiltration. Lipoproteins were separated according to size using gel filtration chromatography from fasting plasma 10 min after injection in two study subjects who were injected with radiolabeled apoA-IV-I and apoA-I. 3 ml of plasma were applied through a flow adaptor to a 1.5 x 75 cm glass column packed with 6% agarose beads (Bio-Gel A-5m, 200-400 mesh; Bio-Rad Labs, Richmond, CA) using an elution buffer of 0.9% NaCl, 0.0 1% EDTA and 0.0 1% NaN3, pH 7.4. The flow rate was 6 ml/h and fractions of 1.5 ml were collected over 24 h at 4°C. The column was calibrated with ultracentrifugally prepared VLDL (d < 1.006 g/ml) and HDL (1.063-1.210 g/ml), as well as with BSA.
Immunoaffinity isolation oflipoproteins. ApoA-I-containing lipoproteins with apoA-II (LpA-I:A-II) and without apoA-II (LpA-I) were isolated from plasma 10 min after injection as previously described (43) in eight study subjects injected with both apoA-IV isoproteins. Briefly, monoclonal antibodies against apoA-I and apoA-II (45) were coupled to CNBr-activated Sepharose 4B (Pharmacia LKB Biotechnology). Plasma was first applied to the anti-apoA-II immunosorbent and apoA-II-containing particles were eluted with 3 M NaSCN. The nonretained fraction from the anti-apoA-II column was then applied to an anti-apoA-I column and the retained apoA-I-containing particles were eluted with 3 M NaSCN. All column samples were counted for apoA-IV-associated radioactivity in order to determine the distribution ofthe radiolabeled apoA-IV in apoA-I-containing lipoproteins.
Ultracentrifugation. Lipoprotein density fractions (VLDL, LDL, HDL, VHDL) were isolated from 5 ml plasma by sequential ultracentrifugation (46) and tube slicing. Radioactivity in the supranatant and infranatant fractions was determined after each centrifugation, and the ratio of radioactivity in the top/(top + bottom) was used to determine the total radioactivity in each density fraction at each time point.
Analytical methods. Plasma apoA-IV was quantitated by a noncompetitive ELISA similar to that previously described (47) . Briefly, rabbit polyclonal antiserum to isolated human apoA-IV was purified using CM Affi-Gel Blue (Bio-Rad Labs), followed by ammonium sulfate precipitation. Microtiter plates were coated with anti-apoA-IV antibodies at a concentration of 1 gig/well. After blocking with 0.8% casein, plasma samples diluted 1:2,000 were added to the wells and incubated at 40C overnight. After washing, the same purified anti-apoA-IV antibodies conjugated with horseradish peroxidase (HRP) and diluted 1:2,000 were added to the wells and incubated at room temperature for 1.5 h. After washing, HRP substrate was added, the reaction stopped in 20 min, and absorbance read at 450 nm by an automated plate reader (Bio-Tek Instruments, Inc., Winooski, VT). A secondary plasma standard was developed after multiple measurements using a validated apoA-IV electroimmunoassay, which was previously described (48) . Plasma cholesterol and triglycerides were quantitated by automated enzyme techniques on a VPSS analyzer (Abbott Labs, North Chicago, IL). HDL cholesterol was determined in plasma after dextran sulfate precipitation (49) . Plasma apoA-I and apoA-II were quantitated by immunoturbidometric assay (Boehringer-Mannheim, Mannheim, Germany).
Statistical comparisons of apoA-IV-1 and apoA-IV-2 plasma kinetic parameters, fractional rate constants, intercepts, and density distributions were made using the paired Student's t test. Linear regression analysis was performed using the least squares method. Means are expressed as ±SEM.
Results
The clinical characteristics of the study subjects are presented in Table I . Values represent the mean of five measurements made during the kinetic study. Their weights and plasma lipid levels remained in steady state throughout the study. There were no significant differences between apoA-IV-1 / 1 homozygotes and apoA-IV-2 /1 heterozygotes in any of the clinical parameters.
The total plasma kinetic parameters of apoA-IV metabolism are displayed in Table II . The mean apoA-IV-1 FCR was 2.42±0.11 d-'. The mean apoA-IV absolute production (or transport) rate was 16.3±1.4 mg/kg/d. Linear regression analysis revealed that plasma apoA-IV concentrations were highly correlated with apoA-IV production rate (r = 0.84, P < 0.001 ) and not correlated with apoA-IV FCR (r = 0.25, P = NS) (Fig. 1) .
The mean FCR of the apoA-IV-2 isoprotein was 2.21±0.10 d-'. Representative plasma curves of apoA-IV-l and apoA-IV-2 from two apoA-IV-2/ I heterozygotes are shown in Fig. 2 . The FCR of apoA-IV-2 was an average of 14±3% slower than that of apoA-IV-1 in the ten subjects who received both labeled apolipoproteins, significantly different by paired t test (P = 0.003). There were no significant differences in apoA-IV metabolism between the apoA-IV-l / 1 homozygotes and the apoA-IV-2/1 heterozygotes. However, the FCR of apoA-IV-2 in the other study subjects. In Fig. 3 A are shown the apoA-IV-2 plasma curves in the apoA-IV-2/2 homozygote, an apoA-IV-2/1 heterozygote, and an apoA-IV-l /1 homozygote who were injected simultaneously with the same radiolabeled apoA-IV-2.
The difference in metabolism between apoA-IV-l and apoA-IV-2 was not simply due to differential extravascular distribution, as illustrated by the representative urine/plasma (U/P) radioactivity ratios in Fig. 4 . The U/P ratios for apoA-IV-2 were consistently lower than those for apoA-IV-in the same subject, indicating a slower rate of degradation of apoA-IV-2. The slower catabolism ofapoA-IV-2 in the apoA-IV-2/2 homozygote can also be seen by the much lower apoA-IV-2/2 U/P ratios in this subject compared with two subjects studied at the same time (Fig. 3 B) . By 4 d the U/P ratios ofapoA-IV-l and apoA-IV-2 were relatively equal, indicating that a slowly turning-over apoA-IV pool is catabolized at a similar rate for both forms of apoA-IV.
The heterogeneity of the U/P ratios over time indicates that there are distinct metabolic pools of apoA-IV with substantially different catabolic rates. The difference between apoA-IV-l and apoA-IV-2 metabolism was further analyzed using the exponentials of the plasma decay curves. The apoA-IV plasma decay curves were each fit to three different exponentials, with fractional rate constants LI, L2, and L3, and intercepts al, a2, and a3 (Table III) . The kinetic difference between apoA-IV-1 and apoA-IV-2 was not due to differences in the fractional rate constants of the exponentials, but rather to significant differences in the intercepts, which represent the apparent distribution of the radiolabeled apolipoproteins among the three components as a fraction ofthe injected dose. Compared with apoA-IV-1, less apoA-IV-2 was associated with the most rapidly turning over component (LI) and more with the more slowly turning over components (L2 and L3).
The distribution of apoA-IV according to lipoprotein particle size was determined by gel filtration chromatography 10 min after injection into two subjects who were injected with radiolabeled apoA-IV-1 and apoA-I (Fig. 5) . By this chromatographic procedure, an average of 83% ofthe '25I-apoA-IV-I and 95% ofthe apoA-IV mass was found to be associated with lipoprotein particles in the HDL and VHDL size range. There were two peaks of apoA-IV-associated radioactivity in this region: one coeluted with the HDL standard and the radiolabeled apoA-I peak and represented 29% ofthe total apoA-IV radioactivity; the other eluted between the HDL and BSA standards and represented 54% of the total apoA-IV radioactivity. There was some radiolabeled apoA-IV in the triglyceride-rich lipoprotein (TRL) fraction but virtually none in the lipid-deficient fraction (LDF). Column Fraction Number The association of radiolabeled apoA-IV-1 and apoA-IV-2 with apoA-I-containing lipoproteins was determined in eight subjects by immunoaffinity chromatography of fasting plasma drawn 10 min after injection (Table IV) . The majority of the apoA-I-associated apoA-IV was found in association with LpA-I:A-II rather than with LpA-I. A total of 71±6% of the apoA-IV-I and 66±4% of the apoA-IV-2 were associated with apoA-I. The differences between apoA-IV-1 and apoA-IV-2 were not statistically significant.
The distribution of radiolabeled apoA-IV-1 and apoA-IV-2 was also determined after sequential ultracentrifugation of plasma from the 10 study subjects who were injected with both Table IV radiolabeled isoproteins (Table V) . 10 min after injection, < 5% of the radioactivity was found in the d < 1.063 g/ml (VLDL + LDL) fraction, but a highly reproducible fraction of the apoA-IV-associated radioactivity was found in the traditional HDL density range (d = 1.063-1.21 g/ml). There was a small but significant difference in the distribution of the two radiolabeled apoA-IV isoproteins: 20.8±1.3% of apoA-IV-1 was found in the HDL range, whereas 23.4±1.0% ofapoA-IV-2 was HDL-associated (P = 0.001 by paired t test). Conversely, in the VHDL range (d = 1.21-1.25 g/ml) there was more apoA-IV-1 than apoA-IV-2. In Fig. 6 are displayed the mean decay curves for HDL-associated (d = 1.063-1.21 g/ml) and non-HDL-associated (total counts minus HDL counts) apoA-IV. In all subjects, the HDL-associated apoA-IV was catabolized significantly more slowly than the non-HDL-associated (P < 0.005 for every time point after 3 h for both apoA-IV isoproteins). 
Discussion
Despite considerable interest in apoA-IV as a potentially important participant in lipoprotein metabolism and reverse cholesterol transport, the plasma kinetics of apoA-IV in humans have not been extensively investigated. There have been three studies ofapoA-IV metabolism in humans, but all involved the injection of radiolabeled apoA-IV which had first been reassociated with a lipoprotein density fraction prior to injection in a limited number of subjects. Ohta et al. (37) performed in vivo studies of radiolabeled human lymph apoA-IV reassociated with lymph TRL, plasma TRL, HDL, or the lipoprotein-deficient fraction (LDF) in five individuals, only one ofwhom was normolipidemic. Studies were carried out for only 2 d and no kinetic parameters were reported for the injected apoA-IV. Ghiselli et al. (38) reported the kinetics ofradiolabeled human lymph apoA-IV reassociated with TRL, HDL, or LDF in six normolipidemic subjects and concluded that the catabolism of apoA-IV within the LDF was faster than that in HDL. Recently, Malmendier et al. (39) reported studies of human serum apoA-IV reassociated with HDL prior to injection in five normolipidemic subjects and found that the average fractional catabolic rate of HDL-associated apoA-IV was only 0.7 d'-l. All of these studies were performed without knowledge of the apoA-IV phenotype of the source of the purified apoA-IV or of the study subjects. In the current investigation, we established the plasma kinetics of total apoA-IV and directly compared the metabolism ofthe two major isoforms ofapoA-IV in normolipidemic subjects of defined apoA-IV phenotype. ApoA-IV-1, the major apoA-IV isoprotein, was found to have a mean FCR of 2.42 d-', making it one of the most rapidly catabolized apolipoproteins in humans. This rapid turnover is supported by recent data from our laboratory (Verges, B., et al., unpublished data) using endogenous labeling of apoA-IV with stable isotopically labeled amino acids. The mean apoA-IV absolute production, or transport, rate was 16.3 mg/kg per d, which is in a range similar to that of apoA-I (50, 51 ) . It has been previously demonstrated that apoA-IV is similar in structure to apoA-I, has excellent access to the interstitial space, promotes cholesterol efflux from cells, activates LCAT, associates with HDL, may modulate CETP activity, and binds specifically to hepatic tissue. The high rate of in vivo apoA-IV transport lends further support to the hypothesis that despite its low steady state concentration relative to apoA-I, apoA-IV may play a role in reverse cholesterol transport in humans.
Plasma concentrations of apoA-I are more highly correlated with apoA-I fractional catabolic rate than with the rate of apoA-I production (50, 52, 53) . In contrast, we found that the major determinant of plasma apoA-IV concentrations was the apoA-IV production rate in these normolipidemic subjects, with no correlation between apoA-IV level and catabolic rate. Although plasma apoA-IV levels have been shown to increase in response to increased dietary fat intake (54) , all subjects in our studies were on a controlled metabolic diet. Hence, the variation in apoA-IV production rate among individuals suggests that nondietary factors, possibly genetic, determine the rate of intestinal apoA-IV synthesis. In several strains of mice, differences in cis-acting elements near the apoA-IV gene have been shown to affect apoA-IV gene expression (55) . Our results suggest that similar genetic variation in apoA-IV gene expression may exist in humans and may be an important determinant of plasma apoA-IV levels.
The metabolism of apoA-IV is highly heterogeneous, as indicated by the U/P ratio curves and the exponentials of the plasma decay curves, suggestive of several kinetic compartments with very different turnover rates. The true distribution of apoA-IV in human plasma has not been established. Early reports indicated that after ultracentrifugation, most of the apoA-IV in fasting plasma was found in the d > 1.21 density range (4, 56, 57) . However, Lagrost et al. (58) found 18% of apoA-IV in the d < 1.21 g/ml density range (mostly HDL) after ultracentrifugation. Using traditional gel filtration chromatography, -20% of plasma apoA-IV has been reported to be associated with HDL (4, 38, 57, 59, 60) . On the other hand, Lagrost et al. (58) , using Superose 12-HR columns (Sigma Chemical Co., St. Louis, MO) on FPLC (which decreases separation time and may improve resolution), found about 70% of apoA-IV mass associated with HDL; they also found that 70% of apoA-IV immunoprecipitated with an antibody to apoA-I (58). Finally, when apoA-IV-containing particles were isolated from plasma by anti-apoA-IV immunoaffinity chromatography and separated by FPLC gel filtration, most ofthe apoA-IV was found in particles in the small HDL range ( 12) .
In our studies, gel filtration chromatography indicated that the majority of the radiolabeled apoA-IV and apoA-IV mass were associated with lipoprotein particles of the HDL and VHDL size range. Immunoaffinity chromatography suggested that a substantial amount of labeled apoA-IV was associated with apoA-I; the majority of this apoA-I-associated apoA-IV was found to be with LpA-I:A-II rather than LpA-I, consistent with a previous report (39) . A portion ofradiolabeled apoA-IV (20-25%) remained consistently associated with HDL even after sequential ultracentrifugation. The catabolic rate of the HDL-associated apoA-IV was substantially slower than that of non-HDL-associated apoA-IV and was similar to that ofradiolabeled apoA-IV reassociated with HDL prior to injection (38, 39) . Furthermore, the tails of the U/P ratio curves had a mean U/P ratio that approached the FCR of apoA-IV injected on HDL (39) . Hence, our data is consistent with the existence ofa pool of HDL-associated apoA-IV which turns over at slower rate than the remainder of plasma apoA-IV.
The discrepancies in the literature concerning the true distribution ofapoA-IV in human plasma may have several possible explanations. First, apoA-IV has very labile binding to lipoproteins, especially HDL (23), and therefore its apparent distribution may be very sensitive to the exact methodology used to isolate the lipoprotein particles, as well as to factors like plasma storage conditions and LCAT and CETP activity. Second, there may be differences in immunoreactivity of apoA-IV on different lipoprotein particles that affect its immunoquantitation in lipoprotein subfractions and may vary among different assays. Finally, we found by both gel filtration and ultracentrifugation that a substantial amount of apoA-IV was present in the VHDL range, which has not traditionally been considered part of HDL but probably represents small dense lipoprotein particles rather than free protein (61 ) .
The FCR of apoA-IV-2 was an average of 14±3% slower than that of apoA-IV-1 in the ten subjects who were injected with both radiotracers, a small but significant difference. Furthermore, the catabolism of apoA-IV-2 was 35% slower in an apoA-IV-2/2 homozygote than the mean apoA-IV-2 FCR in the other 12 subjects who were injected with this tracer. The U/P ratio curves confirmed the metabolic difference between apoA-IV-l and apoA-IV-2, as the U/P ratios for apoA-IV-2 were consistently lower than those for apoA-IV-1. Analysis of the individual plasma curve exponentials suggested that the major reason for the slower catabolism of apoA-IV-2 than apoA-IV-1 was a preferential distribution of apoA-IV-2 in more slowly turning-over compartments, rather than differences in the fractional rate constants themselves. This was supported by the finding that a higher fraction of apoA-IV-2 was found in association with HDL after sequential ultracentrifugation, and is consistent with the observation that apoA-IV-2 has more alpha-helical structure and higher affinity for phospholipids than does apoA-IV-1 (36). ApoA-IV can self-associate and is likely to exist at least in part as a homodimer under physiologic conditions (62) , possibly in association with some lipid and even other apolipoproteins (61) . A difference between the two isoproteins in rate ofself-association could affect their distribution and influence their kinetic rates, as was previously proposed (62) . The apoA-IV-2 isoprotein had an even slower catabolic rate in the apoA-IV-2/2 homozygote than in the apoA-IV-2/ 1 heterozygotes, possibly because in the homozygote all apoA-IV dimers are true homodimers of apoA-IV-2 rather than "mixed" apoA-IV-2/ 1 dimers. Further studies will be needed to explore these hypotheses.
In summary, apoA-IV has a rapid fractional catabolic rate ten times that of apoA-I and an absolute transport rate comparable to that of apoA-I. In contrast to apoA-I, plasma concentrations of apoA-IV in normolipidemic subjects are determined by the apoA-IV production rate. The catabolism of the common variant apoA-IV-2 isoprotein is slower than that of the wild-type apoA-IV-1, primarily because ofan altered distribution in the plasma. This may be related to the apparent effects of the apoA-IV-2 allele on plasma lipid and apolipoprotein concentrations. These studies provide further insight into the complex nature of apoA-IV metabolism in humans.
